Everyone Wins In Deal Between BMS And The Medicines Co.

Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.

Big Pharma is all about streamlining these days and Bristol-Myers Squibb Co. is no different. The company inked a deal on Dec. 12 with The Medicines Co. to effectively offload an asset that no longer fits into its strategic focus.

The deal will be mutually beneficial to both companies – allowing Bristol-Myers to continue to collect royalties on a product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance